These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23400497)

  • 21. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
    He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
    J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
    Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
    Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
    Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
    Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's patients.
    Polychronis S; Dervenoulas G; Yousaf T; Niccolini F; Pagano G; Politis M
    PLoS One; 2019; 14(7):e0214352. PubMed ID: 31344030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Segmental progression of cardinal motor symptoms in Parkinson's disease: a pilot study suggesting a practical approach to rate disease course in the early stages.
    Picillo M; Amboni M; Erro R; Vitale C; Longo K; Pellecchia MT; Cozzolino A; Moccia M; Allocca R; Barone P
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1143-8. PubMed ID: 24041938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum insulin-like growth factor-1 levels in neurodegenerative diseases.
    Suzuki K; Suzuki S; Ishii Y; Fujita H; Matsubara T; Okamura M; Sakuramoto H; Hirata K
    Acta Neurol Scand; 2019 Jun; 139(6):563-567. PubMed ID: 30903695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
    Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease.
    Picillo M; Santangelo G; Moccia M; Erro R; Amboni M; Prestipino E; Longo K; Vitale C; Spina E; Orefice G; Barone P; Pellecchia MT
    J Neural Transm (Vienna); 2016 Apr; 123(4):371-7. PubMed ID: 26739446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
    Santiago JA; Potashkin JA
    PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between [
    Ramani L; Malek N; Patterson J; Nissen T; Newman EJ
    Acta Neurol Scand; 2017 Apr; 135(4):400-406. PubMed ID: 27255673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology.
    Boertien JM; van der Zee S; Chrysou A; Gerritsen MJJ; Jansonius NM; Spikman JM; van Laar T;
    BMC Neurol; 2020 Jun; 20(1):245. PubMed ID: 32534583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is insulin-like growth factor-1 involved in Parkinson's disease development?
    Castilla-Cortázar I; Aguirre GA; Femat-Roldán G; Martín-Estal I; Espinosa L
    J Transl Med; 2020 Feb; 18(1):70. PubMed ID: 32046737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
    Jalali MS; Saki G; Farbood Y; Azandeh SS; Mansouri E; Ghasemi Dehcheshmeh M; Sarkaki A
    J Chem Neuroanat; 2021 Apr; 113():101921. PubMed ID: 33600923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.
    Wills AM; Pérez A; Wang J; Su X; Morgan J; Rajan SS; Leehey MA; Pontone GM; Chou KL; Umeh C; Mari Z; Boyd J;
    JAMA Neurol; 2016 Mar; 73(3):321-8. PubMed ID: 26751506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients.
    Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J
    Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
    Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
    J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.